Age is an issue of mind over matter — h/t Mark Twain — but early ALS clinical trial results from Google-backed aging-disease ...

Calico, Google 's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint ...

Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal ...

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It's the first ...

(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...

The first data have now emerged from a drug Calico developed. It failed. The pill, known as fosigotifator, was not designed to slow aging itself. The Food and Drug Administration does not consider ...